

**Table S1.** The clinical features, results of imaging and metabolic studies of epilepsy patients in the PED-C.

PT	Sex	Age range (years)	OA (years)	Clinical characteristics, comorbidities	Epilepsy	EEG	Brain MRI	Treatment	Uniquely altered metabolites	Z-score
1	M	11-15	0-5	ID (severe), central hypotonia, dystonic movements	G40.2 G41.9	Frontocentral epileptiform discharges in sleep	Normal brain structures, minimal enlargement of lateral ventricles	No treatment (Oxcarbazepine was started later)	1-stearoyl-2-arachidonoyl-GPI (18:0/20:4)	-2.56 (< 2.5 pc)
2	M	16-20	0-5	ID (severe), brain structural anomaly, spasticity, weight and/or growth < -2.5 SD, microcephaly	G40.2	Epileptiform discharges from occipital areas in sleep	Cavum septi pellucidi, cavum Vergae, pachygyria, hyperintense white matter signal in T1 and T2, calcifications	Lamotrigine Valproic acid Baclofen Tizanidine	Valine Phenylalanine	-2.32 (< 2.5 pc) -2.91 (< 2.5 pc)
3	F	11-15	0-5	ID (profound), dysmorphic features, brain structural anomaly, central hypotonia, weight and/or growth<-2.5SD	G40.2 G40.4	Multifocal epileptiform activity	Regional polymicrogyria, hypoplastic corpus callosum, cerebellar hypoplasia, large arachnoid cyst, subependymal heterotopias, calcifications	Vigabatrin Lamotrigine	2-aminoadipate 6-oxopiperidine-2-carboxylate	3.26 (> 97.5 pc) 3.15 (> 97.5 pc)
4	M	0-5	0-5	ID (profound), dysmorphic features, brain structural anomaly, spasticity, microcephaly	G40.4	Generalized and multifocal epileptiform activity	Biparietal schizencephaly, frontotemporal pachygyria/agyria, dysgenesis of corpus callosum, colpocephaly	Levetiracetam Vigabatrin Folic acid	No unique changes	
5	M	6-10	6-10	ID (severe), autism spectrum disorder, dysmorphic features, central hypotonia, coarctation of aorta. Clinically Kabuki syndrome	G40.3	Epileptiform activity over the right hemisphere in sleep	Enlargement of the left lateral ventricle	Valproic acid	Asparagine Indoleacetate 1-oleoyl-2-linoleoyl-GPE (18:1/18:2)* 1-stearoyl-2-arachidonoyl-GPE (18:0/20:4)	-2.37 (< 2.5 pc) -2.46 (< 2.5 pc) -2.71 (< 2.5 pc) -2.12 (< 2.5 pc)
6	F	16-20	11-15	ID (profound), (auto)aggression, dysmorphic features, brain structural anomaly, weight and/or height < -2.5 SD, microcephaly	G40.2	Epileptiform activity over the left hemisphere	Hypoplasia of corpus callosum, enlargement of lateral ventricles	Levetiracetam Estradiol Levothyroxin	N6-acetyllysine 5-hydroxylysine Cystine N-delta-acetylornithine Myristoleoylcarnitine (C14:1)* 2-hydroxydecanoate 1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6)* Phosphatidylcholine (16:0/22:5n3, 18:1/20:4)*	2.41 (> 97.5 pc) 2.00 (> 97.5 pc) 1.83 (> 97.5 pc) 2.05 (> 97.5 pc) -2.53 (< 2.5 pc) -1.81 (< 2.5 pc) 2.21 (> 97.5 pc) 2.41 (> 97.5 pc)

PT	Sex	Age range (years)	OA (years)	Clinical characteristics, comorbidities	Epilepsy	EEG	Brain MRI	Treatment	Uniquely altered metabolites	Z-score
									1-margaroyl-2-arachidonoyl-GPC (17:0/20:4)* Sphingomyelin (d18:1/18:1, d18:2/18:0) Sphingomyelin (d18:1/20:1, d18:2/20:0)* Sphingomyelin (d18:1/20:2, d18:2/20:1, d16:1/22:2)* Sphingomyelin (d18:2/24:1, d18:1/24:2)* Xanthine Urate	2.28 (> 97.5 pc) 2.08 (> 97.5 pc) 2.32 (> 97.5 pc) 1.96 (> 97.5 pc) 2.49 (> 97.5 pc) 2.52 (> 97.5 pc) -15.95 (< 2.5 pc)
7	M	11-15	0-5	ID, autism spectrum disorder, brain structural anomaly	G40.3 G40.4	Hypsarythmia	Cobblestone lissencephaly, subcortical white matter T2 hyperintense patches in frontal, parietal and occipital regions	Amantadine Risperidon Lamotrigine Ethosuximide	Ethylmalonate 5alpha-androstan-3beta,17beta-diol disulfate 5alpha-androstan-3beta,17beta-diol monosulfate (2) Androstenediol (3beta,17beta) disulfate (1) Androstenediol (3beta,17beta) monosulfate (1) 2-aminooctanoate 3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF)	-1.91 (< 2.5 pc) 1.71 (>97.5 pc) 1.74 (>97.5 pc) 2.12 (>97.5 pc) 1.98 (>97.5 pc) -2.34 (< 2.5 pc) 2.77 (>97.5 pc)
8	F	11-15	0-5	ID (severe), (auto)aggression, muscle weakness/hypotonia, ataxia, weight > 2.5 SD, height < - 2.5 SD, macrocephaly	G40.2 G40.8	Multifocal epileptiform activity	Enlargement of lateral ventricles, cerebellar atrophy	Levetiracetam Somatotropin	Bilirubin (E,E)* 16a-hydroxy DHEA 3-sulfate 1-stearoyl-2-dihomo-linolenoyl-GPI (18:0/20:3n3 or 6)*	2.11 (>97.5 pc) 1.64 (>97.5 pc) 1.83 (>97.5 pc)
9	F	0-5	0-5	ID, (auto)aggression, autism spectrum disorder, dysmorphic features, brain structural anomaly, central hypotonia	G40.2	Multiregional epileptiform activity dex>sin, epileptic encephalopathy	Temporomesial hippocampal sclerosis, slight hypomyelination, abnormal cerebral white matter	Diazepam Sulthiame Phenytoin	Homocitrulline Myristate (14:0) Palmitate (16:0) Margarate (17:0) Stearate (18:0) Nonadecanoate (19:0) Myristoleate (14:1n5) 10-heptadecenoate (17:1n7) 10-nonadecenoate (19:1n9) Docosapentaenoate (n3 DPA; 22:5n3) Hexadecadienoate (16:2n6) (14 or 15)-methylpalmitate (a17:0 or i17:0) (16 or 17)-methylstearate (a19:0 or i19:0) Tetradecanedioate (C14-DC) Hexadecanedioate (C16-DC) 1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3)* 1-oleoyl-2-docosahexaenoyl-GPC (18:1/22:6)* 1-linoleoyl-2-linolenoyl-GPC (18:2/18:3)* 1-stearoyl-2-oleoyl-GPI (18:0/18:1) N-stearoyl-sphinganine (d18:0/18:0) N-stearoyl-sphingosine (d18:1/18:0) Myristoyl dihydrosphingomyelin (d18:0/14:0) Sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0)* Sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0)* Cholesterol Carotene diol (1)	5.74 (>97.5 pc) 2.29 (>97.5 pc) 1.93 (>97.5 pc) 2.38 (>97.5 pc) 2.41 (>97.5 pc) 3.04 (>97.5 pc) 2.47 (>97.5 pc) 2.66 (>97.5 pc) 2.08 (>97.5 pc) 2.41 (>97.5 pc) 2.17 (>97.5 pc) 2.74 (>97.5 pc) 2.63 (>97.5 pc) 3.47 (>97.5 pc) 2.65 (>97.5 pc) 1.85 (>97.5 pc) 1.96 (>97.5 pc) 1.98 (>97.5 pc) 1.99 (>97.5 pc) 2.06 (>97.5 pc) 2.11 (>97.5 pc) 1.73 (>97.5 pc) 1.96 (>97.5 pc) 1.82 (>97.5 pc) 3.35 (>97.5 pc) 2.18 (>97.5 pc)

PT	Sex	Age range (years)	OA (years)	Clinical characteristics, comorbidities	Epilepsy	EEG	Brain MRI	Treatment	Uniquely altered metabolites	Z-score
10	F	11-15	0-5	ID (severe), autism spectrum disorder, (auto)aggression, dysmorphic features, central hypotonia, weight and/or height < -2.5 SD, microcephaly	G40.2 G41.9	No interictal epileptiform activity	Cavum septi pellucidi	No treatment	Lignoceroyl sphingomyelin (d18:1/24:0) Sphingomyelin (d18:2/18:1)*	-2.36 (< 2.5 pc) -1.96 (< 2.5 pc)
11	M	6-10	0-5	Speech developmental delay, brain structural anomaly. Seizure free for past 3 years. Variant in CSNK2A1 considered to be the cause of epilepsy	G40.3	Frequent absences during wakefulness and light sleep, bilateral epileptiform activity interictally	Suspected malrotation of the left hippocampus	Lamotrigin Topiramate Clonazepam	3-(3-hydroxyphenyl)propionate 3-hydroxyhippurate	2.49 (>97.5 pc) 2.17 (>97.5 pc)

PT – patient number, Age range – age range at sample collection, OA – age range at epilepsy onset, MRI – magnet resonance imaging, EEG – electroencephalogram, Treatment – medications used at sample collection, ID – intellectual disability, GPI – Phosphatidylinositol, GPE – Phosphatidylethanolamine, GPC – Phosphatidylcholine, \* – the identification on metabolites marked with an asterisk is based on mass spectrometry data but no reference standards are currently available to verify the identity.

ICD-10 diagnosis codes: G40.2 – Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, G40.3 – Generalized idiopathic epilepsy and epileptic syndromes, G40.4 – Infantile spasms, G40.8 – Other epilepsy and recurrent seizures, G41.9 – Status epilepticus